Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
RESEARCH TOOLSreports
Springworks Therapeutics (SWTX) Stock Price & Analysis
301 Followers
SWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.00 - $53.92
Previous Close$44.84
Volume630.43K
Average Volume (3M)969.89K
Market Cap
$3.32B
Enterprise Value$2.91B
Total Cash (Recent Filing)$422.42M
Total Debt (Recent Filing)$7.33M
Price to Earnings (P/E)-9.0
Beta0.43
Next Earnings
Jul 31, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.99
Shares Outstanding74,086,425
10 Day Avg. Volume618,388
30 Day Avg. Volume969,890
Standard Deviation0.18
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-19.29
Forecast
1Y Price Target
$66.14Price Target Upside47.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Springworks Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialMirdametinib shows a superior profile relative to selumetinib, indicating a smooth approval process and potential market launch.
Financial PerformanceOGSIVEO generated $21.0M in revenue, beating both the estimate and consensus.
Market Acceptance And GrowthDemand for Ogsiveo has been mostly organic with minimal inventory stocking, suggesting a strong market acceptance.
Bears Say
Drug ApprovalThe probability of approval for nirogacestat in combination with a BCMA-targeted agent has been lowered, delaying its market entry.
EarningsThe company recorded a net loss of $1.18 per share.
Financial ForecastAnalyst lowers the 12-month price target for the company's stock to $52.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SWTX FAQ
What was Springworks Therapeutics’s price range in the past 12 months?
Springworks Therapeutics lowest stock price was $18.00 and its highest was $53.92 in the past 12 months.
What is Springworks Therapeutics’s market cap?
Currently, no data Available
When is Springworks Therapeutics’s upcoming earnings report date?
Springworks Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 73 days.
How were Springworks Therapeutics’s earnings last quarter?
Springworks Therapeutics released its earnings results on May 02, 2024. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.172 by -$0.008.
Is Springworks Therapeutics overvalued?
According to Wall Street analysts Springworks Therapeutics’s price is currently Undervalued.
Does Springworks Therapeutics pay dividends?
Springworks Therapeutics does not currently pay dividends.
What is Springworks Therapeutics’s EPS estimate?
Springworks Therapeutics’s EPS estimate is -$1.12.
How many shares outstanding does Springworks Therapeutics have?
Springworks Therapeutics has 74,086,426 shares outstanding.
What happened to Springworks Therapeutics’s price movement after its last earnings report?
Springworks Therapeutics reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.172. Following the earnings report the stock price went down -7.451%.
Which hedge fund is a major shareholder of Springworks Therapeutics?
Among the largest hedge funds holding Springworks Therapeutics’s share is Maverick Capital ltd. It holds Springworks Therapeutics’s shares valued at 105M.
---
Springworks Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.14 (47.50% Upside)
$66.14 (47.50% Upside)
Blogger Sentiment
Bearish
SWTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.11%
12-Months-Change
Fundamentals
Return on Equity
-63.12%
Trailing 12-Months
Asset Growth
15.40%
Trailing 12-Months
Company Description
Springworks Therapeutics
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
---
SWTX Earnings Call
Q1 2024
0:00 / 0:00
---
SWTX Stock 12 Month Forecast
Average Price Target
$66.14
▲(47.50% Upside)
Technical Analysis
Best Analysts Covering SWTX
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+34.50%
reiterated a buy rating 17 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +34.50% per trade.
---